Terconazole Cream for Non-Candida albicansFungalVaginitis: Results of a Retrospective Analysis

摘要

Objective:Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicansspecies, terconazole cream has not been been studied in patients with these infections. Wesought to assess the clinical and mycological efficacy of terconazole cream in women with non-C.albicansvaginitis.Methods:The records of patients who had received a 7-day course of terconazole cream forculture-proved non-C. albicansvaginitis were reviewed. Data with regard to patient demographics,clinical and mycologic response to therapy within 1 month of treatment, and outcome with otherantifungal therapies were analyzed.Results:Twenty-eight patients received terconazole cream for non-C. albicansinfections. Threepatients did not return for follow-up. The median age was 45 years. Seven (28%) patients werenulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had receivedterconazole within the 6 months prior to referral. Overall, there were 20C. glabratacases, 3C.parapsilosis, and 2C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noteda resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P=0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effectedin 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %)patients remained uncured.Conclusions:Terconazole cream may be an appropriate first-line treatment for non C. albicansvaginitis, even in patients who have previously received the drug. Infect. Dis. Obstet. Gynecol.8:240–243, 2000.